Radical resection and outcome for malignant tumors of the pancreatic body and tail

Table 1 The relationship between resection rate and clinicopathological variables (mean ± SD) n (%)

Clinicopathological variables	Radicality
	R0 resection (n = 49)	R1 + R2 resection (n = 22)	Bypass or laparotomy (n = 49)
Tumor size (cm)	4.8 ± 1.3b	7.9 ± 2.2	11.0 ± 3.8
Histopathological type
Ductal adenocarcinoma (n = 60)	15 (25.0)b	10 (16.7)	35 (58.3)
Cystadenocarcinomas (n = 39)	25 (64.1)	7 (17.9)	7 (17.9)
Others (n = 21)	7 (33.3)	6 (28.6)	8 (38.1)
Lymph node metastasis	16 (32.7)b	19 (86.4)	43 (87.8)
Peri-organ involvement1	26 (53.1)b	18 (81.8)	40 (81.6)
TNM staging
Stage I + II (n = 17)	17 (100.0)b	0	0
Stage III (n = 16)	14 (87.5)	2 (12.5)	0 (0)
Stage IVA (n = 34)	18 (52.9)2	7 (20.6)	9 (26.5)
Stage IVB (n = 53)	0	13 (24.5)	40 (75.5)

^bP < 0.01 vs R1 + R2 resection and bypass or laparotomy;

¹Peri-organ involvement included spleen, transverse colon, left kidney, stomach and their vessels;

²Six gastric malignant tumors with pancreatic invasion, one pancreatic metastasis from renal cell carcinoma after operation, 11 pancreatic cystadenocarcinomas with splenic invasion.

Table 2 Histopathological diagnosis of 120 patients with resected pancreatic malignant tumor

Histopathological classification	Cases
Ductal adenocarcinoma	60
Invaded and metastatic tumor	7
Pancreas invaded from gastrointestinal stromal tumor	6
Pancreatic metastasis from renal cell carcinoma	1
Cystadenocarcinomas	39
Serous cystadenocarcinomas	30
Mucinous cystadenocarcinomas	9
Endocrine malignant tumor	14
Insulinoma	3
Gastrinoma	11

Table 3 The relationship between surgical radicality and survival n (%)

Surgical radicality	Cases with follow-up	1-yr survival	3-yr survival	5-yr survival
R0 resection (n = 49)	47	26 (55.3)b	15 (31.9)b	5 (10.6)b
R1 + R2 (palliative) resection (n = 22)	21	2 (9.5)b	0	0
Bypass or laparotomy (n = 49)	48	6 (12.5)b	0	0
Non-surgical treatment (n = 94)	81	1 (1.2)b	0	0
Total (n = 214)	197	25 (12.7)	15 (7.6)	5 (2.5)

^bP < 0.01 vs non-R0 resection, the 1-, 3- and 5-year survival rates were significantly longer.

Table 4 Influence of splenectomy on survival in patients with malignant tumors of the pancreatic body and tail after radical pancreatectomy n (%)

Procedures	Complications	Cases with follow-up	1-yr survival	3-yr survival	5-yr survival
Combined spleen and pancreatectomy (n = 22)	7 (31.8)a	21	9 (42.9)a	6 (28.6)a	2 (9.5)a
Spleen-preserving pancreatectomy (n = 27)	7 (25.9)	26	16 (61.5)	9 (34.6)	3 (11.5)
Total (n = 49)	14 (26.5)	47	25 (53.2)	15 (31.9)	5 (10.6)

^aP > 0.05.